This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I50 (Heart failure) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Congestive heart failure (CHF), HFrEF (systolic heart failure), HFpEF (diastolic heart failure), HFmrEF (heart failure with mid-range ejection fraction), acute heart failure, chronic heart failure, right heart failure, left heart failure |
| C. Adult onset | Prevalence increases with age, reaching about 10% at age 70 and older. Ischemic heart disease and hypertension are the main causes, and the 5-year mortality of Korean heart failure patients is about 50%. |
| 1. History | Harvey's theory of blood circulation (1628) is the foundation for understanding heart failure. Treatment innovations followed in the order of RAAS blockade, beta-blockers, sacubitril/valsartan, and SGLT2 inhibitors. |
| 2. Causes | Causes include coronary artery disease (most common), hypertension, valvular disease, cardiomyopathy, myocarditis, toxicity (alcohol, anticancer drugs), and endocrine disorders. |
| 3. Genetics | Genes related to inherited cardiomyopathy, such as TTN (titin), LMNA, MYH7, and MYBPC3, contribute to the development of heart failure and are identified in about 35% of familial dilated cardiomyopathy. |
| 4. General epidemiology | About 64 million patients worldwide. One of the most common causes of hospitalization in people aged 65 and older. Prevalence in Korea about 1–2%, with more than about 100,000 hospitalizations per year. |
| 5. Pathophysiology | Myocardial injury → ventricular remodeling → RAAS and SNS overactivation → edema and congestion. In HFpEF, ventricular stiffness, impaired relaxation, and microvascular inflammation are key. |
| 6. Symptoms | Dyspnea (most common), paroxysmal nocturnal dyspnea, orthopnea, lower limb edema, fatigue, exercise intolerance. Severity assessed by NYHA classification. |
| 7. Signs | Characteristic findings are elevated jugular venous pressure, pulmonary crackles, S3 gallop rhythm, lower limb pitting edema, ascites, hepatomegaly, and displaced apical impulse. |
| 8. Screening | BNP/NT-proBNP is the primary screening biomarker. Echocardiographic screening recommended in groups at risk of heart failure (hypertension, diabetes, coronary artery disease). |
| 9. Diagnosis | Confirmed by symptoms/signs + elevated BNP/NT-proBNP + echocardiography (LVEF, structure, diastolic function). ECG, chest X-ray, and blood tests performed concurrently. |
| 10. Treatment | Quadruple therapy for HFrEF: ACEI/ARB/ARNI + beta-blocker + MRA + SGLT2 inhibitor. CRT, ICD, heart transplantation, and LVAD are applied in high-risk groups. |
| 11. Prognosis | 5-year mortality about 50%. Optimal medical therapy can reduce HFrEF mortality by 30–40%. Treatments for HFpEF are advancing, but mortality remains high. |
| 12. Prevention | Early treatment of hypertension, coronary artery disease, and diabetes, maintaining a healthy weight, abstaining from alcohol, and cardiac monitoring during use of cardiotoxic anticancer drugs are the keys to prevention. |
| 13. References | 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction … and 9 other papers |
The history of heart failure has developed over thousands of years. Ancient Egyptian papyri (around 1550 BC) contain descriptions of fluid retention and shortness of breath, but the foundation of modern understanding began in 1628 when William Harvey established the principles of blood circulation in Exercitatio Anatomica de Motu Cordis et Sanguinis. In the 18th century, William Withering described the diuretic and cardiotonic effects of digitalis (foxglove) in 1785, opening the first era of drug treatment for heart failure.
In the 20th century, understanding of the pathophysiology of heart failure deepened. The introduction of diuretics (thiazides, loop diuretics) in the 1950s–60s greatly improved management of congestive symptoms, and the introduction of hemodynamic monitoring (Swan-Ganz catheter) in the 1970s made invasive treatment of acute heart failure possible. The 1980s–90s were the era of renin-angiotensin-aldosterone system (RAAS) blockers. The CONSENSUS (1987) and SOLVD (1991) studies proved that an ACE inhibitor (enalapril) significantly reduces mortality in HFrEF patients, and the RALES (1999) study demonstrated the additional survival benefit of an aldosterone antagonist (spironolactone).
Paradoxically, beta-blockers were long considered contraindicated in heart failure because of their negative inotropic effect, but the treatment paradigm changed when large studies such as MERIT-HF (1999) and COPERNICUS (2001) proved that metoprolol and carvedilol reduce HFrEF mortality by 34% and 35%, respectively. In 2014, the PARADIGM-HF study demonstrated that sacubitril/valsartan (ARNI) further reduced HFrEF cardiovascular mortality by 20% compared with enalapril, making ARNI the new standard replacing ACE inhibitors. In 2019–2020, the DAPA-HF and EMPEROR-Reduced studies proved that SGLT2 inhibitors (dapagliflozin, empagliflozin) significantly reduce death and worsening heart failure in HFrEF regardless of the presence of diabetes. The current standard treatment for HFrEF has evolved into quadruple therapy, in which these four drugs (ARNI, beta-blocker, MRA, SGLT2 inhibitor) are started early and simultaneously.
Heart failure is a condition in which, due to structural or functional abnormalities of the heart, adequate cardiac output cannot be maintained, or abnormally high filling pressures are required for normal cardiac output. Causes are broadly classified into myocardial injury, pressure and volume overload, rhythm disorders, and filling disorders.
Coronary artery disease (ischemic heart disease) is the most common cause of heart failure in Western countries (about 60–70%). The mechanisms are myocardial loss due to acute myocardial infarction, hibernating myocardium due to chronic ischemia, and reduced contractile function due to scar tissue. In hypertensive heart disease, long-standing pressure overload causes left ventricular hypertrophy and fibrosis, leading first to diastolic dysfunction (HFpEF) and later to reduced systolic function (HFrEF). Among valvular diseases, aortic stenosis and mitral regurgitation cause heart failure through pressure and volume overload, respectively.
Cardiomyopathy is a structural and functional abnormality of the myocardium itself due to various causes, including dilated (DCM), hypertrophic (HCM), restrictive (RCM), and arrhythmogenic (ARVC) types. Causes of toxic myocardial injury include alcohol, cocaine, amphetamines, anticancer chemotherapeutic agents (anthracyclines, trastuzumab), and radiation therapy. Among endocrine disorders, hyperthyroidism and hypothyroidism, diabetes, and growth hormone abnormalities cause heart failure. Nutritional deficiencies (thiamine deficiency, selenium deficiency) are also rare but correctable causes.
Heart failure is a complex polygenic disease, but when inherited cardiomyopathy is the cause, single-gene variants play a decisive role. Causative gene variants are identified in about 35–40% of familial dilated cardiomyopathy (familial DCM). The TTN (titin) gene encodes the elastic protein of the myocardium, and truncating variants, found in about 18–25% of familial DCM, are the most common cause. LMNA (lamin A/C) variants cause cardiac laminopathy combining conduction disorders, ventricular arrhythmias, and DCM, and because the risk of sudden cardiac death is high, they are an indication for prophylactic ICD implantation.
MYH7 (β-myosin heavy chain) and MYBPC3 (myosin-binding protein C) are the most common causative genes of hypertrophic cardiomyopathy (HCM) (accounting for about 70–75% of HCM) and are also found rarely in DCM. SCN5A variants are found together with conduction disorders in some DCM. PLN (phospholamban) variants cause impaired calcium handling through abnormality of a SERCA2a regulatory protein and are associated with DCM. Many polygenic variants associated with heart failure risk are also being discovered through GWAS, and polygenic risk scores (PRS) using them are being studied for heart failure prediction.
Heart failure is a major public health problem with about 64 million patients worldwide. Prevalence in the general adult population is about 1–2%, but rises sharply to about 10% at age 70 and older. In the United States, about 1 million people are newly diagnosed with heart failure each year, and it is one of the most common causes of hospitalization in people aged 65 and older. In Korea, according to National Health Insurance Service data, the number of prevalent heart failure patients is estimated at more than about 300,000 as of 2021 and continues to increase due to population aging.
HFpEF (LVEF ≥50%) accounts for about 50–55% of all heart failure, HFrEF (LVEF ≤40%) for about 35–40%, and HFmrEF (LVEF 41–49%) for about 10–15%. HFpEF shows a stronger association with advanced age, female sex, obesity, hypertension, and diabetes. About 50–60% of heart failure patients have accompanying atrial fibrillation, which is a major precipitating factor of worsening heart failure. The heart failure–related 30-day readmission rate is high at about 20–25%, indicating the importance of post-discharge management.
The pathophysiology of heart failure consists of a multistage compensation–decompensation process after myocardial injury. When cardiac output decreases due to initial myocardial injury (myocardial infarction, hypertension, toxicity, etc.), the body makes compensatory adaptations by activating the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS).
Short-term compensation includes increased heart rate, peripheral vasoconstriction, and sodium and water retention, which maintain blood pressure and tissue perfusion. However, when this neurohormonal activation persists chronically, structural and functional changes of the left ventricle (cardiac remodeling) progress. Ventricular dilation (eccentric hypertrophy), cardiomyocyte hypertrophy, extracellular matrix fibrosis, and cardiomyocyte death (apoptosis and necrosis) occur in combination, forming a vicious cycle that further worsens ventricular function.
The mechanism of HFpEF differs from that of HFrEF. In HFpEF, left ventricular systolic function (LVEF) is preserved, but impaired left ventricular diastolic filling (diastolic dysfunction), increased ventricular stiffness, and elevated pulmonary capillary wedge pressure (PCWP) are key. In recent research, a multifactorial model has drawn attention in which comorbidities such as obesity, hypertension, diabetes, and kidney disease, through systemic inflammation and oxidative stress, cause myocardial microvascular endothelial dysfunction, reduced cGMP-PKG signaling, and decreased titin phosphorylation, promoting ventricular stiffness.
Symptoms of heart failure result from reduced cardiac output and pulmonary and systemic congestion. Dyspnea is the most common symptom; at first it appears only during exercise, but as the disease progresses it gradually occurs with light activity or at rest. Orthopnea is a symptom in which dyspnea worsens in the lying position so that the number of pillows must be increased, reflecting increased left ventricular filling pressure. Paroxysmal nocturnal dyspnea (PND) is a symptom of suddenly waking from sleep with severe breathlessness, caused by worsening pulmonary congestion as body fluid redistributes at night.
Fatigue and exercise intolerance result from reduced cardiac output and reduced muscle blood flow, and patients complain of excessive fatigue in daily activities. Lower limb edema is the accumulation of fluid in the lower limbs by gravity in right or biventricular heart failure, starting at the ankles and progressing to the entire lower limb. The European Society of Cardiology assesses the symptom severity of heart failure using the New York Heart Association (NYHA) functional classification (classes I–IV). NYHA IV is the most severe stage, with heart failure symptoms even at rest.
The main signs observed on physical examination in heart failure are as follows. Elevated jugular venous pressure (JVP) is the most important sign reflecting elevated right atrial pressure; distension of the right jugular vein 4 cm or more above the sternal angle at 45 degrees is judged a significant elevation. Accurate JVP measurement is important for assessing heart failure severity and monitoring treatment response.
Pulmonary crackles reflect fluid accumulation in the alveoli due to left heart failure and are heard on inspiration in both lower lung fields. An S3 gallop rhythm is an early diastolic ventricular filling sound that occurs when blood enters a dilated ventricle in heart failure and is a strong indicator of reduced cardiac output. Lower limb pitting edema leaves an indentation on pressure at the ankles and lower legs, and in severe cases progresses to the thighs and extends to inguinal edema, scrotal edema, and ascites. Lateral displacement of the apex beat reflects left ventricular dilation. In severe heart failure, cardiac cachexia, cyanosis of the tongue, hands, and feet, and hypotension are observed.
The screening approach for early detection of heart failure focuses on high-risk groups. High-risk groups include patients with hypertension, coronary artery disease, diabetes, obesity, those receiving cardiotoxic anticancer treatment, and those with a family history of heart failure.
BNP (B-type natriuretic peptide) and NT-proBNP are the most useful biomarkers of heart failure. BNP <35 pg/mL or NT-proBNP <125 pg/mL makes chronic heart failure very unlikely, and in acute heart failure, BNP <100 pg/mL or NT-proBNP <300 pg/mL makes heart failure unlikely. When BNP is elevated in asymptomatic patients at risk of heart failure (Stage A, B), echocardiography is performed to evaluate structural abnormalities.
Echocardiography is the key test that noninvasively evaluates LVEF, ventricular size and wall thickness, diastolic function, and valve abnormalities. In patients receiving cardiotoxic anticancer drugs (anthracyclines, etc.), regular echocardiography and troponin monitoring before, during, and after treatment are recommended (cardio-oncology approach). Regular echocardiography may also be considered in asymptomatic hypertensive and diabetic patients at high risk of heart failure.
The diagnosis of heart failure is based on a comprehensive evaluation of symptoms and signs, echocardiography, and biomarkers. The 2021 ESC guideline and the 2022 KSHF guideline present algorithms for the diagnosis of heart failure.
In the non-acute setting, when BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL and symptoms are present, the diagnosis is confirmed by echocardiography. In acute heart failure, BNP ≥100 pg/mL or NT-proBNP ≥300 pg/mL (applying age-specific upper limits) are the diagnostic reference values. Echocardiography classifies heart failure as HFrEF (≤40%), HFmrEF (41~49%), or HFpEF (≥50%) by LVEF measurement and evaluates diastolic function (E/e' ratio, left atrial size, tricuspid regurgitation velocity), ventricular size, and valve abnormalities. ECG evaluates arrhythmia, conduction disorders, ischemic changes, and left ventricular hypertrophy. Chest X-ray is checked for cardiomegaly (cardiothoracic ratio > 0.5), increased hilar shadows, Kerley B lines (interstitial pulmonary edema), and alveolar opacities (alveolar pulmonary edema). Blood tests including BMP (basic metabolic panel), thyroid function, iron, CBC, and liver function are included in the evaluation of underlying causes.
Treatment of heart failure differs by type (HFrEF/HFmrEF/HFpEF), and approaches to acute and chronic heart failure are distinct.
The standard treatment for HFrEF (LVEF ≤40%) is currently quadruple therapy: (1) ARNI (sacubitril/valsartan) or ACE inhibitor/ARB, (2) beta-blocker (carvedilol, metoprolol, bisoprolol), (3) MRA (aldosterone antagonist) (spironolactone, eplerenone), (4) SGLT2 inhibitor (dapagliflozin, empagliflozin). Starting these four drugs early, simultaneously or sequentially, is recommended. Diuretics (loop diuretics: furosemide, torsemide) are used to control congestive symptoms but do not improve survival.
When LVEF is ≤35% and LBBB with QRS ≥150 ms is present after optimal medical therapy, CRT (cardiac resynchronization therapy) is recommended. With LVEF ≤35% in nonischemic cardiomyopathy or more than 40 days after myocardial infarction, ICD implantation is recommended for primary prevention. In end-stage heart failure (end-stage HF), heart transplantation or an LVAD (left ventricular assist device) is applied as a bridge to transplantation or as destination therapy. The current standard treatment for HFpEF is SGLT2 inhibitors (CLASS I recommendation; EMPEROR-Preserved, DELIVER studies), diuretics (symptom control), and active management of comorbidities (hypertension, diabetes, atrial fibrillation, obesity).
The prognosis of heart failure has long been known to be worse than that of many cancers, with 5-year mortality after diagnosis reaching about 50%. However, with the recent introduction of quadruple therapy, the prognosis of HFrEF patients is improving meaningfully. According to a large meta-analysis, quadruple therapy reduces cardiovascular death or heart failure hospitalization by about 60–70% compared with placebo.
Major factors worsening prognosis include advanced age, low LVEF, severe renal dysfunction, diabetes, anemia, accompanying atrial fibrillation, and repeated hospitalizations. Heart failure hospitalization is a strong predictor of worsening prognosis; the readmission rate within 30 days after discharge reaches 20–25%, and each hospitalization worsens the long-term prognosis. HFpEF shows high mortality similar to HFrEF, but specific mortality-reducing therapy has only recently been established (SGLT2 inhibitors). The recent TRED-HF study reported that complete recovery of cardiac function (normalization of LVEF and size) is possible in some patients with dilated cardiomyopathy, drawing attention to the concept of "heart failure remission."
Heart failure prevention is divided by risk stage. In Stage A (risk factors present, no heart failure), active treatment of risk factors (hypertension, dyslipidemia, diabetes, obesity, smoking) is key. Achieving target blood pressure in hypertensive patients reduces the risk of developing heart failure by about 40–50%. In diabetic patients, SGLT2 inhibitors show an independent heart failure–preventive effect beyond glycemic control, and their use is expanding in Stage A/B patients as well.
In cancer patients receiving cardiotoxic anticancer drugs (anthracyclines, trastuzumab, immune checkpoint inhibitors, etc.), baseline cardiac function evaluation, troponin and BNP monitoring during treatment, and prophylactic administration of ACEI/beta-blockers when needed have been reported to be effective in preventing cardiotoxicity. Abstaining from alcohol is essential for preventing alcoholic cardiomyopathy, and in those who already have alcoholic cardiomyopathy, cardiac function may recover with complete abstinence. Regular aerobic exercise reduces the risk of heart failure, and even in established heart failure, exercise therapy through cardiac rehabilitation programs is effective in improving NYHA functional class and quality of life.
Writing Committee Members; Maddox TM, Januzzi JL Jr, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2024;83(9):1444-1488. DOI: 10.1016/j.jacc.2023.12.024. PMID: 38466244.
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368. PMID: 34447992.
McMurray JJV, Packer M, Desai AS, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993-1004. DOI: 10.1056/NEJMoa1409077. PMID: 25176015.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. DOI: 10.1056/NEJMoa1911303. PMID: 31535829.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. DOI: 10.1056/NEJMoa2107038. PMID: 34449189.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717. DOI: 10.1056/NEJM199909023411001. PMID: 10471456.
Mo Z, Fang H, He Z, et al. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis. Clin Cardiol. 2023;46(12):1443-1452. DOI: 10.1002/clc.24085. PMID: 37465885.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. PMID: 27206819.
Kucharska-Newton AM, Couper DJ, Pankow JS, et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol. 2010;47(Suppl 1):161-168. DOI: 10.1007/s00592-010-0177-y. PMID: 20443060.
Tromp J, Ferreira JP, Janwanishstaporn S, et al. Heart failure around the world: differences in epidemiology, treatment and outcomes. Eur J Heart Fail. 2019;21(11):1311-1317. DOI: 10.1002/ejhf.1592. PMID: 31423712.